Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years

Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 20-23 Years After Neonatal Immunization

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02166671

Enrollment

Registered

2014-06-18

Start date

2014-04-25

Completion date

2015-12-31

Last updated

2017-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B Vaccination

Brief summary

This study will evaluate the humoral and cellular immune responses to a hepatitis B vaccine booster in healthy adults which received a full course of neonatal hepatitis B vaccination 20-23 years ago.

Interventions

BIOLOGICALHBV booster vaccination 1dose

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy adults 20-25 years old

Exclusion criteria

* Hepatitis B surface antigen (+) * Hepatitis B core antibody (+) * any history of liver disorders including hepatitis * HIV Ag or Ab(+)

Design outcomes

Primary

Measure	Time frame
change of HBsAb titer	28 days after HBV booster vaccination

Secondary

Measure	Time frame
HBsAg-specific cell mediated immunity	28 days after HBV booster vaccination

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026